![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Response rates are similar for patients with and without advanced fibrosis/cirrhosis, and highest with peginterferon alfa-2a (40KD) 180 μg for 48 weeks in the NEPTUNE study
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
M. McKenna,1 Y. Cui,2 S. Thompson,3 C. Wat1 1Roche Products Limited, Welwyn Garden City, UK; 2Shanghai Roche Pharmaceuticals Ltd, Beijing, China; 3Chugai Pharmaceutical Co. Ltd, Tokyo, Japan
![AASLD1.gif](../images/111711/111711-8/AASLD1.gif)
![AASLD2.gif](../images/111711/111711-8/AASLD2.gif)
![AASLD3.gif](../images/111711/111711-8/AASLD3.gif)
![AASLD4.gif](../images/111711/111711-8/AASLD4.gif)
![AASLD5.gif](../images/111711/111711-8/AASLD5.gif)
![AASLD6.gif](../images/111711/111711-8/AASLD6.gif)
![AASLD7.gif](../images/111711/111711-8/AASLD7.gif)
![AASLD8.gif](../images/111711/111711-8/AASLD8.gif)
![AASLD9.gif](../images/111711/111711-8/AASLD9.gif)
![AASLD10.gif](../images/111711/111711-8/AASLD10.gif)
![AASLD11.gif](../images/111711/111711-8/AASLD11.gif)
![AASLD12.gif](../images/111711/111711-8/AASLD12.gif)
![AASLD13.gif](../images/111711/111711-8/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|